Vaidya Sane Ayurved LaboratoriesShare price, financial results, shareholding and management
- Market cap
- ₹143 cr
- Stock P/E
- 15.9peers 25.3
- Book value
- ₹68.2
- Price to book
- 1.99
- EV / operating profit
- 9.4
- Market cap to sales
- 1.34
- ROCE · FY26
- 16.9%
- ROE · FY26
- 13.4%
- ROE, 3-year average
- 9.9%
- Operating margin · FY26
- 14.4%peers 13.2%
- Sales growth, 3 years
- 2.6%
- Profit growth, 3 years
- 21.6%
- Debt to equity
- 0.04peers 0.11
- Borrowings
- ₹2.6 cr
- Interest cover
- 13.7×
- Cash from business / op. profit
- 35%
- Debtor days
- 35
- Pledged
- 0.00%
- Promoter holding
- 66.34%
- Change in promoter holding
- 0.00 pts
- Shareholders
- 764
- 52-week high / low
- ₹335 / ₹130
- Dividend yield
- 0.00%
- Face value
- ₹10
Tap or hover on any figure for what it means. Our arithmetic on reported figures, at the latest close.
Vaidya Sane Ayurved Laboratories share price chart
Close on 6 Nov 2026 · -12.49% on the day · Vol 13,200
Daily prices to 6 Nov 2026, adjusted for splits and bonuses. Closing prices only: check the exchange for the live price.
Share price returns
To the close of 6 Nov 2026
- 1 month
- -19.5%
- 3 months
- -28.0%
- 6 months
- -46.3%
- 1 year
- -48.5%
- Traded a day, 20 days
- ₹0.05 cr
- Taken for delivery
- 92%
Business growth
Sales and net profit, from the reported results
| Sales | Profit | |
|---|---|---|
| FY26 on FY25 | +19% | +25% |
| 3 years, a year | +3% | +22% |
| Latest half, H2 FY26 | +19% | +39% |
About Vaidya Sane Ayurved Laboratories: business, products and customers
Vaidya Sane Ayurved Laboratories runs Madhavbaug, a chain of mostly franchised clinics and a few hospitals that treat heart disease, diabetes and other lifestyle illnesses with Ayurveda. Its shares trade on NSE Emerge.
Vaidya Sane Ayurved Laboratories runs Madhavbaug, a chain of about 320 clinics and four hospitals that treat heart disease, diabetes, high blood pressure and obesity with Ayurvedic therapies, diet kits and medicines, alongside modern tests such as ECG and 2D echo. Most clinics are run by franchise doctors; the company runs some clinics itself and owns the hospitals at Khopoli, Kondhali near Nagpur, Visakhapatnam and Vadodara. Two fully owned subsidiaries, Dynamic Remedies and UV Ayurgen Pharma, make its medicines and diet foods.
The franchise model shapes the reported numbers. When a franchise clinic takes ₹100, the managing director says ₹35 to ₹40 comes to the company, mostly as medicines and kits it sells to the clinic, so reported revenue is well below what patients pay across the network (see key points). Patients are won through marketing, which the managing director says makes up most of other expenses, the largest cost; a new call centre lifted costs in the second half of FY26, and branding spend of about ₹7 cr, including the Sonu Sood campaign, is written off over five years rather than at once.
Read more about the business
The company is moving patients from cheaper preventive plans towards year-long disease reversal programmes, which it says bring ₹50,000 to ₹60,000 a year per patient against ₹10,000 to ₹13,000. It is enlarging the Khopoli hospital, agreed in May 2026 to acquire Parasnath Healthcare, a chain of about 70 joint pain franchise clinics, for about ₹6 cr in cash, and signed a profit sharing partnership for a therapy centre in Malaysia. Hospital revenue depends on beds filling and on insurance tie-ups, which the company had at Khopoli and Nagpur in November 2025 and was seeking at the other two.
The prospectus names no single rival but describes competition from large hospital chains, clinic chains and well funded health-tech start-ups offering diabetes reversal. The November 2025 presentation names Apollo, VLCC and Manipal Group among big players setting up wellness centres with traditional remedies.
From the May 2026 and November 2025 earnings calls, the November 2025 presentation, the audited FY26 results filed with NSE in June 2026, the July 2026 CEO announcement, the FY24 annual report and the 2022 prospectus. No FY25 or FY26 annual report was available.
Read the deeper study ↓In its favour
- It has little debt for its size: debt to equity 0.04.
- The promoters own a large part of the company: 66.34%.
To watch
- Whether margins recover in the half year to September 2026 after the call centre and marketing costs of the second half of FY26 (H2 FY26 earnings call, May 2026, p.9 and p.10).
- Progress at the Khopoli hospital towards 150 beds by March 2027, and the first results that include Parasnath Healthcare (H2 FY26 earnings call, May 2026, p.11, p.13 and p.14; FY26 results filing, p.42).
- Conversion of the 34,00,000 warrants issued in FY26, convertible after 18 months, after two earlier rounds of warrant money were forfeited (FY26 results filing, p.11, p.24 and p.41).
- Follow-up on the FY26 audit remarks (weak login controls, an overdue deposit with Easy Ayurveda, a going-concern doubt at subsidiary F-Health Accelerators, tax demands under appeal) and the June 2026 NSE query on the results format (FY26 results filing, p.1, p.6, p.9, p.10, p.12).
- Customers take longer to pay than before: 35 days in FY26, against 21 in FY19.
From the company's documents first, then the reported figures read by fixed rules, the same for every company. Facts, not a view on the shares.
Vaidya Sane Ayurved Laboratories revenue and profit growth
Half-yearly results · Profit and lossSales have grown slowly. Last year profit grew faster than sales, so the company kept more from each rupee of sales.
SME companies report every six months. In the latest half, sales were higher than in the same half a year before. Profit grew faster than sales.
Vaidya Sane Ayurved Laboratories half-yearly results
SME companies report every six months · ₹ crore
| H1FY23 | H2FY23 | H1FY24 | H2FY24 | H1FY25 | H2FY25 | H1FY26 | H2FY26 | |
|---|---|---|---|---|---|---|---|---|
| Sales | 46 | 54 | 51 | 48 | 42 | 48 | 49.94 | 56.96 |
| Expenses | 41 | 50 | 48 | 46 | 36 | 40 | 41.32 | 50.17 |
| Operating profit | 4 | 4 | 3 | 2 | 6 | 9 | 8.62 | 6.80 |
| OPM | 9.0% | 7.0% | 5.0% | 3.8% | 14.0% | 18.0% | 17.3% | 11.9% |
| Interest | 0 | 0 | 0 | 0 | 0 | 1 | 0.10 | 0.75 |
| Depreciation | 1 | 1 | 2 | 2 | 2 | 2 | 3 | 3.13 |
| Profit before tax | 4 | 3 | 2 | 1 | 5 | 5 | 6.47 | 4.34 |
| Net profit | 3 | 2 | 1 | 1 | 4 | 3 | 4.83 | 4.16 |
Vaidya Sane Ayurved Laboratories profit and loss
Full years to March, FY19 to FY26 · ₹ crore, consolidated where reported
| FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|---|
| Sales | 62.30 | 74.61 | 52.01 | 74.24 | 99 | 99 | 89.85 | 106.91 |
| Expenses | 59.20 | 71.70 | 47.54 | 66.92 | 91 | 95 | 76.34 | 91.49 |
| Operating profit | 3.10 | 2.91 | 4.47 | 7.32 | 9 | 5 | 13.50 | 15.42 |
| OPM | 5.0% | 3.9% | 8.6% | 9.9% | 9.0% | 4.5% | 15.0% | 14.4% |
| Other income | 0.07 | 0.07 | -1.06 | 0.34 | 1 | 2 | 1.86 | 2.37 |
| Interest | 0.70 | 1.20 | 0.51 | 0.63 | 1 | 0 | 0.10 | 0.85 |
| Depreciation | 1.59 | 2.23 | 2.45 | 2.29 | 3 | 3 | 4.16 | 6.13 |
| Exceptional and other items | · | · | · | · | · | -1 | -1.20 | · |
| Profit before tax | 0.88 | -0.45 | 0.45 | 4.74 | 6 | 3 | 9.90 | 10.81 |
| Tax rate | 43.2% | 24.4% | 15.6% | 26.8% | 16.7% | 33.3% | 27.6% | 16.8% |
| Net profit | 0.50 | -0.56 | 0.39 | 3.47 | 5 | 2 | 7.17 | 8.99 |
| EPS ₹ | 0.71 | -0.80 | 0.56 | 3.30 | 4.59 | 1.88 | 6.76 | 8.51 |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% | 5.0% | 0.0% | 0.0% | 0.0% |
The years to FY24 come rounded to the nearest crore in the source.
Exceptional and other items: profit before tax beyond operating profit, other income, interest and depreciation, such as one-off items or a share of associates' profit, as reported.
Vaidya Sane Ayurved Laboratories profitability
Margins and returns on capitalLast year the company kept about as much from each rupee of sales as the year before. It earns a moderate return on the money it uses.
Operating margin, every year
Per cent of sales kept before interest, depreciation and tax
| FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|---|
| Operating margin | 5.0% | 3.9% | 8.6% | 9.9% | 9.0% | 4.5% | 15.0% | 14.4% |
| Tax rate | 43.2% | 24.4% | 15.6% | 26.8% | 16.7% | 33.3% | 27.6% | 16.8% |
| ROCE | · | 4.7% | 7.7% | 22.5% | 18.0% | 6.1% | 16.4% | 16.9% |
| ROE | · | -6.6% | 4.3% | 15.2% | 13.0% | 4.1% | 12.1% | 13.4% |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% | 5.0% | 0.0% | 0.0% | 0.0% |
Vaidya Sane Ayurved Laboratories debt and cash flow
Balance sheet · Cash flow · Working capitalThe company's own money, its net worth, has grown. It borrowed much more last year. Its loans are smaller than its own money. Last year the business brought in less cash than it showed as profit, so part of the profit is still to be collected. It spent more on assets and investments than the business brought in, and raised the rest from loans or shares. Customers take longer to pay than they did in FY24, which ties up more of the company's money in unpaid bills.
Bars below the line are cash going out.
Vaidya Sane Ayurved Laboratories balance sheet
At each 31 March · ₹ crore
| FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0.05 | 0.05 | 0.05 | 10.51 | 11 | 11 | 10.52 | 10.52 |
| Reserves | 8.74 | 8.17 | 9.72 | 25.37 | 30 | 45 | 52.02 | 61.16 |
| Net worth | 8.79 | 8.22 | 9.77 | 35.88 | 41 | 56 | 62.54 | 71.68 |
| Borrowings | 8.67 | 5.97 | 1.02 | 1.06 | 0 | 2 | 1.46 | 2.59 |
| Other liabilities | 11.41 | 14.93 | 15.02 | 13.07 | 14 | 12 | 12.71 | 30.24 |
| Total liabilities | 28.87 | 29.12 | 25.81 | 50.01 | 55 | 70 | 76.71 | 104.51 |
| Fixed assets | 15.66 | 15.51 | 17.16 | 17.01 | 21 | 28 | 33.66 | 34.33 |
| Capital work in progress | 2.02 | 3.79 | 0.38 | 1.23 | 2 | 2 | 1 | 2 |
| Investments | 0.02 | 0.02 | 0.01 | 21.49 | 15 | 18 | 21.31 | 39.88 |
| Other assets | 11.17 | 9.80 | 8.26 | 10.28 | 17 | 22 | 20.74 | 28.30 |
| Receivables | · | · | · | · | · | · | 7.54 | 10.23 |
| Inventory | · | · | · | · | · | · | 3.76 | 3.65 |
| Cash | · | · | · | · | · | · | 2.36 | 0.44 |
| Trade payables | · | · | · | · | · | · | 6.86 | 6.57 |
Vaidya Sane Ayurved Laboratories cash flow
₹ crore
| FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 1.58 | 7.72 | 5.77 | -13.31 | 0 | -1 | 10.60 | 5.41 |
| Cash from investing | -10.05 | -3.93 | -0.67 | -7.52 | 1 | -13 | -10.08 | -24.04 |
| Cash from financing | 7.71 | -3.63 | -5.26 | 22.49 | -1 | 15 | -0.54 | 16.71 |
| Net cash flow | -0.76 | 0.16 | -0.16 | 1.66 | 0 | 1 | -0.02 | -1.92 |
| Capital spending | · | · | · | · | · | · | 8.45 | 7.88 |
Working capital
Days
| FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|---|
| Debtor days | 21 | 12 | 19 | 18 | 22 | 22 | 31 | 35 |
| Inventory days | 77 | 49 | 35 | · | · | 58 | 82 | 70 |
| Days payable | 138 | 138 | 147 | · | · | 101 | 149 | 127 |
| Cash conversion cycle | -39 | -77 | -93 | 18 | 22 | -20 | -37 | -21 |
| Working capital days | -58 | -55 | -54 | -30 | -2 | 5 | 7 | 112 |
Vaidya Sane Ayurved Laboratories peers and competitors
Listed SME companies in the same industryBy sales, Vaidya Sane Ayurved Laboratories is number 6 of the 15 listed SME companies in healthcare equipment & supplies.
Each company's latest full year and its latest close; companies the exchange puts in the same industry, whose businesses can differ a good deal. A list, not a comparison of their shares.
| Company | Market cap ₹ cr | P/E | Sales ₹ cr | Profit ₹ cr | Op. margin | Debt/equity |
|---|---|---|---|---|---|---|
| Mohini Health & Hygiene | 57 | - | 144 | -16.7 | -1.8% | 0.39 |
| Vaidya Sane Ayurved Laboratories | 143 | 15.9 | 107 | 9 | 14.4% | 0.04 |
| Royal Sense | 39 | 5.5 | 103 | 7 | 11.0% | 0.33 |
| Prevest Denpro | 472 | 23.6 | 72 | 20 | 35.0% | 0.00 |
| Aprameya Engineering | 187 | 36.6 | 55.1 | 5.1 | 19.1% | 0.10 |
| Earkart | 172 | 35.0 | 54 | 4.9 | 15.4% | 0.00 |
| Avience Biomedicals | 149 | 17.0 | 52.5 | 8.8 | 28.4% | 0.92 |
| Amkay Products | 58 | 25.3 | 42 | 2.3 | 9.2% | 0.15 |
| Galaxy Medicare | 29 | 8.4 | 40 | 3.4 | 10.6% | 0.10 |
| KMS Medisurgi | 44 | 175.3 | 12.2 | 0.3 | 7.6% | 0.09 |
| Transpact Enterprises | 4 | 45.7 | 0.2 | 0.1 | 66.7% | 0.11 |
| Median of the 10 others | 58 | 25.3 | 53.3 | 4.2 | 13.2% | 0.11 |
Vaidya Sane Ayurved Laboratories shareholding pattern
Promoters, FIIs, DIIs, HNIs and small holdersThe promoters own more than half the company. Big foreign and Indian funds own very little. The number of shareholders is about the same.
Vaidya Sane Ayurved Laboratories shareholding pattern
Per cent of shares, from the patterns filed with the exchange. Tap + to see everyone holding 1% or more in that group. HNIs and small holders show only where the pattern was filed in full.
| Dec 23 | Mar 24 | Sep 24 | Mar 25 | Sep 25 | Dec 25 | Mar 26 | Sep 26 | |
|---|---|---|---|---|---|---|---|---|
| Promoters | 66.34% | 66.34% | 66.34% | 66.34% | 66.34% | 66.34% | 66.34% | 66.34% |
| Foreign investors (FIIs) | 0.00% | 0.00% | - | - | - | - | - | - |
| Indian institutions (DIIs) | 0.00% | 0.00% | - | - | 0.21% | - | - | - |
| HNIs (over ₹2 lakh each) | 9.85% | 10.11% | 12.58% | 10.80% | 11.92% | 11.42% | 11.17% | 12.29% |
| Small holders (up to ₹2 lakh) | 12.46% | 12.58% | 9.66% | 11.14% | 9.88% | 10.21% | 9.93% | 10.56% |
| Companies and others | 11.35% | 10.97% | 11.42% | 11.72% | 11.65% | 12.03% | 12.56% | 10.81% |
| Number of shareholders | 846 | 881 | 821 | 787 | 712 | 700 | 671 | 764 |
The named holders are at 30 Sept 2026, beside 31 March 2026, each under the group the pattern files them in.
Vaidya Sane Ayurved Laboratories study: the business from its own documents
Read from 10 of the company's own documentsVaidya Sane Ayurved Laboratories so far
From the company's own record
- 23 Feb 2022Listed on NSE Emerge
- 30 Sept 2026Promoters at 66.34%
- 24 Aug 2023Highest close since listing, ₹301.31
Vaidya Sane Ayurved Laboratories key facts from the filings
Each figure with the document it comes from
- Revenue
- ₹106.9 cr
- FY26 consolidated revenue, up from ₹89.9 cr, but short of the ₹115 cr to ₹120 cr the company guided in November 2025.FY26 results filing, p.27; H1 FY26 earnings call, November 2025, p.5
- Profit
- ₹8.99 cr
- FY26 consolidated profit after tax, against ₹7.15 cr in FY25.FY26 results filing, p.27
- Clinics
- About 320
- Clinics in May 2026, the same count as in September 2025; most are franchises.H2 FY26 earnings call, May 2026, p.3; Presentation, November 2025, p.17
- Company's share of franchise sales
- 35% to 40%
- Of every ₹100 a franchise clinic takes, the part that comes to the company, mostly as medicines and kits.H2 FY26 earnings call, May 2026, p.7
- Network collections
- ₹145.6 cr
- Collected across company and franchise clinics and hospitals in FY25, when the company's own revenue was ₹89.9 cr.Presentation, November 2025, p.14 and p.36
Show 5 more facts
- New patients
- 1,18,223
- New patients in FY26, against 82,049 in FY25; the aim is about two lakh a year by FY28.H2 FY26 earnings call, May 2026, p.3; Presentation, November 2025, p.20
- Warrant money received
- ₹15.76 cr
- Upfront part of 34,00,000 warrants issued to outside investors in FY26 for a Kondhali hospital, working capital and general purposes; held in bank deposits in May 2026.FY26 results filing, p.41; H2 FY26 earnings call, May 2026, p.20
- Warrant money forfeited
- ₹13.43 cr
- Paid upfront on warrants issued in April and August 2023, the April issue to the promoter group; forfeited when they lapsed in November 2024 and February 2025, and credited to capital reserve.FY26 results filing, p.24 and p.38
- Parasnath purchase
- ₹6 cr cash
- For all of Parasnath Healthcare, about 70 joint pain franchise clinics; not in the FY26 accounts.FY26 results filing, p.42 and p.44; H2 FY26 earnings call, May 2026, p.12 and p.13
- New CEO
- From 24 July 2026
- D. Ramakrishna took over as CEO; Rohit Madhav Sane stays managing director.Exchange announcement, 24 July 2026, p.1 and p.3
What the company said, and what happened
The company's own statements, attributed, set against what it later reported; not newboard's estimates
On the May 2026 call the company said it aims for about two lakh new patients a year and revenue of ₹250 cr to ₹300 cr by FY28 with EBITDA margins above 20%, and that the Khopoli hospital, now 50 beds, should have 150 beds built by March 2027. For FY27 the managing director gave different revenue targets in the opening remarks and in later answers on the same call, so no FY27 figure is shown here. In November 2025 it guided FY26 revenue of ₹115 cr to ₹120 cr; reported revenue was ₹106.9 cr.
| What management said | When | What happened |
|---|---|---|
| FY26 revenue of ₹115 cr to ₹120 cr | Nov 2025 call | ₹106.9 cr |
| FY26 EBITDA margin of 17% to 18% | Nov 2025 call | About 14.4% excluding other income (our arithmetic) |
| 40 to 50 new clinics in FY26 | Nov 2025 call | About 320 clinics in May 2026, as in September 2025 |
| Main board migration within 6 to 7 months | Nov 2025 call | Decision still a couple of months away in May 2026 |
Is it a good business? Six questions
Each answer is about that one question, read from the documents; tap one for the evidence. Not a view on the shares.
The company earns from patients on year-long Ayurveda programmes and from medicines it sells to its franchise clinics, a model that needs little capital.
Its weak spots are growth that keeps falling short of its own targets, a heavy marketing bill to win each new patient, and frequent changes in top management.
AverageCan it set its own prices?Partly. Year-long disease reversal plans carry a high price, but each patient has to be won with marketing.
AverageHow strong is it against rivals?It is a known niche brand, but it faces hospital chains, clinic chains and funded health-tech start-ups.
StrongWho are its customers?Many individual patients across hundreds of clinics, so no single customer matters; most reach it through franchise doctors.
StrongDoes it need a lot of money?Not much. Clinics are mostly franchised and borrowing is small, and the hospital expansion is planned from internal money and warrant funds.
WatchCan it keep finding new work?Patient numbers are rising, but the clinic network has not grown and franchise numbers were flat for three years.
WatchDo good and bad years swing a lot?More than a clinic chain might suggest. Revenue fell in FY25 and margins dropped in the second half of FY26 when marketing and call-centre costs rose.
Who runs Vaidya Sane Ayurved Laboratories?
Promoters, directors and officers; tap a name for the background
RMRohit Madhav SanePromoter, Chairman and Managing Director · holds 66.29%
MBBS from Dr. Babasaheb Ambedkar Marathwada University, Aurangabad (2001) and a Fellowship in Cardiac Rehabilitation from Apollo Hospital; founded Madhavbaug and devised its Sampurna Hriday Shuddhikaran heart treatment, per the prospectus, and a director since March 2005. The FY24 annual report records a resignation as CEO from 31 August 2023, with Shripad Ramchandra Upasani appointed CEO; FY26 filings in May 2026 are signed as Managing Director and CEO, and on 23 July 2026 Rohit Madhav Sane resigned as CEO citing organisational restructuring, while remaining managing director. Terms at the IPO were a basic salary of ₹60 lakh a year plus up to ₹1 cr of incentive. The prospectus lists a civil suit over a land sale in Maval, Pune, seeking the sale or ₹49 lakh damages, and a trespass complaint at Khalapur in which the High Court quashed the FIR.
Prospectus, January 2022, p.97, p.99, p.100, p.160 and p.161; Annual report FY24, p.4; FY26 results filing, p.24; Exchange announcement, 24 July 2026, p.1VBVidyut Bipin GhagWhole Time Director
BAMS from Ayurved Mahavidyalay, Sion, Mumbai (Maharashtra University of Health Sciences) and a postgraduate diploma in healthcare administration from Welingkar; with the company since 2006 as Chief Administrative Officer and medico-legal consultant. The prospectus lists franchise management, medicine supply, procurement and costing among the duties; whole-time director since September 2021.
Presentation, November 2025, p.10; Prospectus, January 2022, p.99 and p.100DRD. RamakrishnaChief Executive Officer
CEO from 24 July 2026. Over 25 years in healthcare, pharmaceuticals, retail and FMCG, with senior roles including CEO, COO and CMO at organisations such as Apollo Hospitals Enterprise, Aster DM Healthcare, Life Medicals (UAE) and Paras Health; holds a Bachelor of Pharmacy and a postgraduate diploma in sales and marketing. Not related to any director, per the announcement.
Exchange announcement, 24 July 2026, p.3NPNarendra PawarChief Financial Officer
CFO from 27 May 2024, after Darshan Shah resigned on 26 May 2024 citing personal reasons. MBA in finance from ICFAI University with 30 years in accounting, finance and tax.
Annual report FY24, p.4 and p.18; Presentation, November 2025, p.11SVSapna VaishnavCompany Secretary and Compliance Officer
In the post from 17 August 2024, after Abhishek Deshpande resigned on 1 June 2024. Associate member of the Institute of Company Secretaries of India with degrees in commerce and law and more than seven years of corporate experience.
Annual report FY24, p.18; Presentation, November 2025, p.11GAGurudatta AminChief Medical Officer
BAMS and MD; with Madhavbaug since 2007 and chief medical officer since 2012, co-author of 63 research publications per the presentation.
Presentation, November 2025, p.11MPMahesh P. KshirsagarIndependent Director
MBBS from Maharashtra Institute of Medical Sciences and Research, Swami Ramanand Teerth University, Nanded, with over 15 years in general practice; on the board since November 2021 and chair of the nomination committee per the FY24 annual report.
Prospectus, January 2022, p.99; Annual report FY24, p.4RVRatnakar Venkappa RaiIndependent Director
B.Com from the University of Bombay with over two decades in liaison, accounts and finance; on the board since September 2021 and chair of the audit committee per the FY24 annual report.
Prospectus, January 2022, p.99; Annual report FY24, p.4Vaidya Sane Ayurved Laboratories latest news and announcements
Announcements · Documents · Corporate actionsWhat changed recently
Each half-year is set against the same half a year earlier
- H2 FY26: sales ₹57 cr (+19%), net profit ₹4.2 cr (+39%) on H2 FY25.
- Shareholding, 30 Sept 2026: promoters unchanged at 66.34%.
Vaidya Sane Ayurved Laboratories announcements
84 on record, latest first; each opens the filing on the exchange
- General UpdatesGeneral UpdatesPDF ↗
- Quarterly Compliance Report on Corporate governance - within 21 days from the enVaidya Sane Ayurved Laboratories Limited has informed regarding Submission of the Compliance Report on Corporate Governance for the Q_ FY 20__-__PDF ↗
- Certificate under SEBI (Depositories and Participants) Regulations, 2018Certificate under SEBI (Depositories and Participants) Regulations, 2018PDF ↗
- Shareholders meetingSrutinizers report of Annual General Meeting held on September 30, 2026. Further, the company has informed the Exchange regarding voting resultsPDF ↗
- Shareholders meetingProceedings of Annual General Meeting held on September 30, 2026PDF ↗
- Trading WindowClosure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015PDF ↗
- Structural Digital DatabaseReply to Query - Submission of PCS Certificate pursuant to NSE mail on SDD Non-CompliancePDF ↗
- General UpdatesGeneral UpdatesPDF ↗
- Shareholders meetingNotice of Annual General Meeting to be held on September 30, 2026PDF ↗
- Outcome of Board MeetingHeld on September 04, 2026PDF ↗
- Statement of deviation(s) or variation(s) under Reg. 32statement of deviation(s) or variation(s) under Reg. 32PDF ↗
- Resignation of Director/KMP/SMPResignation of Director/KMP/SMPPDF ↗
Vaidya Sane Ayurved Laboratories annual reports, earnings calls and documents
Every document links to its source; “read” marks those this page is built from
Vaidya Sane Ayurved Laboratories share split, bonus and dividends
From the corporate actions the company announces on the exchange
No share split, bonus issue or dividend is on record since listing.
Checks we ran on Vaidya Sane Ayurved Laboratories' data · 10
Before any number shows, it goes through the same checks. A figure that fails is held back, never shown as if it were right.
- !For H2FY25 the exchange filing's profit lines do not add up as read, so the figures shown are from the results page instead.
- ✓Balance sheet totals add up for FY25 and FY26.
- ✓Market cap uses the share count in the latest shareholding pattern (1,05,13,450 shares).
- ✓The share capital in the FY26 results matches the share count in the shareholding pattern.
- ✓Promoter pledge figures are within possible limits in every shareholding pattern shown.
- ✓Promoter and public holdings add up to 100% in every shareholding pattern shown.
- ✓The two half-years of FY26 add up to the full-year sales.
- ✓Earnings per share moves in line with profit across the years shown.
- ✓Revenue and profit are reported for every year shown, FY19 to FY26.
- iPrices run to the close on 14 Oct 2026, from the exchange's daily figures.
Questions people ask about Vaidya Sane Ayurved Laboratories
What does Vaidya Sane Ayurved Laboratories do?
Vaidya Sane Ayurved Laboratories runs Madhavbaug, a chain of mostly franchised clinics and a few hospitals that treat heart disease, diabetes and other lifestyle illnesses with Ayurveda. Its shares trade on NSE Emerge.
What is the share price of Vaidya Sane Ayurved Laboratories?
₹136 at the close on 6 Nov 2026, from the exchange's daily figures.
What is the market cap of Vaidya Sane Ayurved Laboratories?
₹143 cr at the close on 6 Nov 2026, on 1,05,13,450 shares.
What is the P/E of Vaidya Sane Ayurved Laboratories?
15.9 times FY26 profit at the close on 6 Nov 2026 (our arithmetic).
What are Vaidya Sane Ayurved Laboratories' revenue and profit?
Revenue ₹107 cr and profit after tax ₹9 cr in FY26.
Who are the promoters of Vaidya Sane Ayurved Laboratories?
Rohit Madhav Sane; promoters held 66.34% at 30 Sept 2026.
What is Vaidya Sane Ayurved Laboratories' website?
madhavbaug.org
More SME companies like Vaidya Sane Ayurved Laboratories
Other listed SME companies in healthcare equipment & supplies, the closest in size first, each read from its own documents.
- Avience BiomedicalsAVIENCE · NSE Emerge · Healthcare Equipment & Supplies · listed 2026Market cap ₹137 cr
- EarkartEARKART · BSE SME · Healthcare Equipment & SuppliesMarket cap ₹153 cr
- Aprameya EngineeringAPRAMEYA · NSE Emerge · Healthcare Equipment & Supplies · listed 2024Market cap ₹248 cr
- Mohini Health & HygieneMHHL · NSE Emerge · Healthcare Equipment & Supplies · listed 2018Market cap ₹49 cr
- Amkay ProductsAMKAY · BSE SME · Healthcare Equipment & SuppliesMarket cap ₹46 cr
- KMS MedisurgiKMSMEDI · BSE SME · Healthcare Equipment & SuppliesMarket cap ₹44 cr
Every listed SME company in Healthcare Equipment & Supplies → · SME companies listed in 2022 →
Built from 3 earnings call transcripts, 3 investor presentations, 2 annual reports, 1 offer document, 1 result filing, 84 exchange announcements, 8 shareholding patterns and 8 years of reported results. Every figure carries its source; where the documents are silent, the page says so.